Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

Levi & Korsinsky, LLP notifies investors in Micron Technology, Inc. ("Micron" or the "Company") of a class action securities ...

RecycLiCo Battery Materials Inc. ("RecycLiCo" or the "Company"), , a pioneer in the field of lithium-ion battery recycling technology, is pleased to announce that it has engaged Penney Capital and ...

Vizient released its new Spend Management Outlook representing a comprehensive analysis of emerging trends and pricing dynamics affecting healthcare.

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...